Clinical trials
Lung Cancer Patients clinical trials
Below are recruiting lung cancer patients clinical trials, each written for real people, not researchers. We’re tracking 1,904 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07096869RecruitingPhase 1
Breast cancer trial comparing two forms of paclitaxel
This study checks if a generic version of paclitaxel protein-bound particles works the same as the brand-name drug in people with breast cancer. It's for patients whose cancer has spread or returned, and who might benefit from this medicine alone.
Changchun, JilinAges 18–75 - NCT07560111RecruitingPhase 2
GC101 cell therapy for advanced lung cancer
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
ShanghaiAges 18–70 - NCT07192900RecruitingPhase 1
Fast TILs for metastatic cancer with pleural disease
This trial tests a new therapy using your own immune cells (called TILs) to treat cancer that has spread to the lining of the lungs. The goal is to see if these cells can shrink tumors and help you feel better.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06923774Recruiting
Registry study for lung biopsy with Ion system
This study collects information from patients having a lung biopsy or nodule localization using the Ion endoluminal system. It aims to understand how well the system works in real-world settings.
Le Plessis-RobinsonAges 18 years+ - NCT07402343RecruitingPhase 2
Tarlatamab for small cell lung cancer brain metastases
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
AmsterdamAges 18 years+ - NCT03769129Recruiting
Pembrolizumab plus lung ablation for advanced lung cancer
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT03872661RecruitingPhase 2
New lung cancer medicines before surgery for unresectable stage III
This Phase 2 trial tests a combination of IBI308 plus bevacizumab and pemetrexed/carboplatin given before surgery, aiming to shrink or control unresectable stage III non-small cell lung cancer. It may help some people become eligible for surgery and improve outcomes, while also testing safety and effectiveness.
Guangzhou, GuangdongAges 18–75 - NCT04086082Recruiting
Marker-free X-ray guidance during lung radiotherapy
This study tests a way to guide lung radiation using X-ray images during treatment, without using implanted tracking markers for every step. It may help doctors target tumors more accurately while you receive external beam radiotherapy.
Melbourne, VictoriaAges 18 years+ - NCT04286841Recruiting
Immunotherapy before lung surgery for early lung cancer
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
Guangzhou, GuangdongAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04324125Recruiting
Chemo plus immune therapy for HER2-positive advanced lung cancer
This trial studies whether adding an immune medicine (an antibody that helps your immune system recognize cancer, such as PD-1) to chemotherapy helps people with advanced HER2-positive non-small cell lung cancer. It may be aimed at people who have never had cancer treatment before.
Changsha, HunanAges 18 years+ - NCT04324151Recruiting
Pembrolizumab plus chemotherapy for lung cancer that may be removed
This trial tests whether adding pembrolizumab (an immune therapy) to standard chemotherapy helps people with certain non-squamous lung cancers that doctors think might be surgically removed. You might be considered if your planned treatment involves a “double platinum” chemotherapy or crizotinib and your cancer is potentially resectable.
Changsha, HunanAges 18 years+ - NCT04324164Recruiting
Testing outcomes with EGFR pills for uncommon lung cancer mutations
This study looks at how well an EGFR-targeted pill (called an EGFR-TKI) works for people with advanced lung cancer that has an uncommon EGFR mutation. It may help doctors understand which patients benefit most and improve survival outcomes.
Changsha, HunanAges 18 years+ - NCT04550104RecruitingPhase 1
Durvalumab with radiation for lung cancer patients
This trial tests adding durvalumab (an immune therapy) to a radiation treatment plan for people with non-small cell lung cancer (NSCLC) who can’t safely have chemotherapy at the same time or surgery first. It aims to improve cancer control after radiation by helping the immune system recognize and fight the tumor.
BelfastAges 18 years+ - NCT04585490RecruitingPhase 3
Testing a personalized add-on treatment after stage III lung cancer
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
Stanford, CaliforniaAges 18 years+ - NCT04591002RecruitingPhase 2
Osimertinib after lung cancer surgery to slow new lung spots
This trial studies osimertinib, a targeted medicine, after surgery to help stop lung cancer from growing or spreading. It’s for people with an early lung cancer that has EGFR mutations and leftover “ground-glass” lung spots in another area.
Seoul, KangnamguAges 30–75 - NCT04617756RecruitingPhase 2
Durvalumab plus chemo before surgery for high-risk upper urinary tract cancer
This trial studies whether durvalumab (an immunotherapy) given with chemotherapy before surgery can improve outcomes for people with high-risk cancer in the kidney pelvis or ureter. It is mainly looking at safety and effectiveness in shrinking or controlling the cancer before treatment continues.
Paris, Paris Cx 20Ages 18 years+ - NCT04624373Recruiting
Test tumor DNA from breath biopsy samples
This study checks tiny pieces of DNA from a sample taken during a breathing-tube biopsy (EBUS-TBNA) to better identify certain lung cancer changes. It may help doctors learn more about the type of lung cancer and, in some cases, why targeted treatments stop working.
ToulouseAges 18–65 - NCT04677205Recruiting
Tumor-to-lymph-node study after lung cancer surgery
This study looks at molecular (biologic) signals in the tumor and nearby lymph nodes after curative surgery for stage IIIA lung cancer. It may help doctors better understand the disease and improve future treatment planning.
BordeauxAges 18 years+ - NCT04686305RecruitingPhase 1
Test drug T-DXd plus immunotherapy, with or without chemotherapy for HER2+ lung cancer
This Phase 1 study tests the safety (and early effectiveness) of T-DXd combined with immunotherapy, sometimes also with chemotherapy, in people with advanced lung cancer that is HER2-positive. It may help if standard options have been limited or your tumor does not have certain genetic changes that already have targeted treatments.
Duarte, CaliforniaAges 18 years+ - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75 - NCT04849481Recruiting
Precision medicine planning for advanced lung cancer tissue testing
This trial uses your tumor sample to guide personalized treatment decisions for certain lung cancers. It may help by matching you to a more targeted plan based on genetic testing and your prior treatment history.
Chiayi CityAges 20 years+ - NCT04875585RecruitingPhase 2
Neoadjuvant and post-surgery immunotherapy for operable lung cancer
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
Innsbruck, TyrolAges 18 years+ - NCT04933903RecruitingPhase 2
Neoadjuvant low-dose radiation plus immunotherapy before lung surgery
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
Providence, Rhode IslandAges 18 years+
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer patients?
- Yes. Clin2 currently lists 1,904 recruiting lung cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.